Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK and Safety Study of Miricorilant Formulations in Healthy Participants
NCT04672499Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Apr 2020
- Primary completion
- Sep 2020
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of miricorilant in Nonalcoholic steatohepatitis (NASH) (6 cohorts), sponsored by Corcept Therapeutics. Primary endpoints: Percentage of Participants with One or More Adverse Events, Percentage of Participants with One or More Serious Adverse Events and 1 more. Started Apr 2020; status: completed.
02
Drugs
miricorilant
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04672499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04672499.